Amedeo Smart

Free Medical Literature Service



Peptic Ulcer

  Free Subscription

Articles published in
J Gastroenterol Hepatol
    August 2022
  1. LI K, Cheng X, Jin R, Han T, et al
    The influence of different proton pump inhibitors and potassium-competitive acid blockers on indomethacin-induced small intestinal injury.
    J Gastroenterol Hepatol. 2022 Aug 8. doi: 10.1111/jgh.15973.
    >> Share

  2. EUSEBI LH, Telese A, Cirota GG, Haidry R, et al
    Effect of gastro-esophageal reflux symptoms on the risk of Barrett's esophagus: A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2022;37:1507-1516.
    >> Share

    July 2022
  3. JUNG YS, Kim S, Kim HY, Noh SJ, et al
    7-day versus 14-day tegoprazan-based triple therapy to treat Helicobacter pylori infection: Real-world evidence.
    J Gastroenterol Hepatol. 2022 Jul 11. doi: 10.1111/jgh.15939.
    >> Share

  4. WANG JW, Hsu PI, Lin MH, Kao JY, et al
    The efficacy of culture-guided versus empirical therapy with high-dose proton pump inhibitor as third-line treatment of Helicobacter pylori infection - A real-world clinical experience.
    J Gastroenterol Hepatol. 2022 Jul 11. doi: 10.1111/jgh.15942.
    >> Share

    June 2022
  5. OUYANG Y, Wang M, Xu YL, Zhu Y, et al
    Amoxicillin-vonoprazan dual therapy for Helicobacter pylori eradication: A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2022 Jun 18. doi: 10.1111/jgh.15917.
    >> Share

    May 2022
  6. KAKIUCHI T, Okuda M, Matsuo M, Fujimoto K, et al
    Smart Gene as an effective noninvasive point-of-care test to detect Helicobacter pylori clarithromycin-resistant mutation.
    J Gastroenterol Hepatol. 2022 May 13. doi: 10.1111/jgh.15887.
    >> Share

  7. PARK DH, In Seo S, Lee KJ, Kim J, et al
    Long-term proton pump inhibitor use and risk of osteoporosis and hip fractures: a nationwide population-based and multicenter cohort study using a common data model.
    J Gastroenterol Hepatol. 2022 May 2. doi: 10.1111/jgh.15879.
    >> Share

  8. XIAO Y, Wu JCY, Lu CL, Tseng PH, et al
    Clinical practice guidelines for esophageal ambulatory reflux monitoring in Chinese adults.
    J Gastroenterol Hepatol. 2022;37:812-822.
    >> Share

    April 2022
  9. HUANG Y, Chen J, Ding Z, Liang X, et al
    Susceptibility testing alone will not reliably achieve high Helicobacter pylori cure rates: A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2022 Apr 17. doi: 10.1111/jgh.15864.
    >> Share

    March 2022
  10. HOU X, Meng F, Wang J, Sha W, et al
    Vonoprazan non-inferior to lansoprazole in treating duodenal ulcer and eradicating Helicobacter pylori in Asian patients.
    J Gastroenterol Hepatol. 2022 Mar 27. doi: 10.1111/jgh.15837.
    >> Share

  11. KUDO Y, Kudo SE, Miyachi H, Ichimasa K, et al
    Changes in halitosis value before and after Helicobacter pylori eradication: A single-institutional prospective study.
    J Gastroenterol Hepatol. 2022 Mar 24. doi: 10.1111/jgh.15835.
    >> Share

  12. SCHUBERT JP, Woodman RJ, Mangoni AA, Rayner CK, et al
    Geospatial analysis of Helicobacter pylori infection in South Australia: should location influence eradication therapy?
    J Gastroenterol Hepatol. 2022 Mar 21. doi: 10.1111/jgh.15832.
    >> Share

  13. YANG W, Yusufu Y, Wang C
    Gastrointestinal: A rare case of upper gastrointestinal bleeding: Splenosis mimicking gastric varices.
    J Gastroenterol Hepatol. 2022 Mar 1. doi: 10.1111/jgh.15795.
    >> Share

    February 2022
  14. KHAN R, Saha S, Gimpaya N, Bansal R, et al
    Outcomes for upper gastrointestinal bleeding during the first wave of the COVID-19 pandemic in the Toronto area.
    J Gastroenterol Hepatol. 2022 Feb 16. doi: 10.1111/jgh.15804.
    >> Share

  15. TERASAKI K, Ueno A, Mizuno C, Shima T, et al
    Gastrointestinal: Pembrolizumab-induced gastric ulcer occurring as an immune-related adverse event.
    J Gastroenterol Hepatol. 2022 Feb 9. doi: 10.1111/jgh.15788.
    >> Share

    December 2021
  16. MANEERATTANAPORN M, Pittayanon R, Patcharatrakul T, Bunchorntavakul C, et al
    Thailand Guideline 2020 for Medical Management of Gastroesophageal Reflux Disease (GERD).
    J Gastroenterol Hepatol. 2021 Dec 14. doi: 10.1111/jgh.15758.
    >> Share

  17. KOUNTOURAS J, Doulberis M, Polyzos SA, Kazakos E, et al
    Impact of Helicobacter pylori-related metabolic syndrome with hyperhomocysteinemia on extragastric pathologies.
    J Gastroenterol Hepatol. 2021 Dec 10. doi: 10.1111/jgh.15753.
    >> Share

  18. REN S, Cai P, Liu Y, Wang T, et al
    Prevalence of Helicobacter pylori infection in China: A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2021 Dec 3. doi: 10.1111/jgh.15751.
    >> Share

    October 2021
  19. YONGWATANA K, Harinwan K, Chirapongsathorn S, Opuchar K, et al
    Curcuma longa Linn Versus Omeprazole in Treatment of Functional Dyspepsia: A Randomized, Double-Blind, Placebo-Controlled Trial.
    J Gastroenterol Hepatol. 2021 Oct 15. doi: 10.1111/jgh.15705.
    >> Share

  20. BUNCHORNTAVAKUL C, Buranathawornsom A
    Randomized Clinical Trial: 7-day Vonoprazan-based versus 14-day Omeprazole-based Triple Therapy for Helicobacter pylori.
    J Gastroenterol Hepatol. 2021 Oct 7. doi: 10.1111/jgh.15700.
    >> Share

    August 2021
  21. UENO M, Mano T, Kayahara T, Mizuno M, et al
    Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding: It's time to step forward.
    J Gastroenterol Hepatol. 2021 Aug 8. doi: 10.1111/jgh.15652.
    >> Share

  22. SIKAVI DR, Cai JX, Carroll TL, Chan WW, et al
    Prevalence and clinical significance of esophageal motility disorders in patients with laryngopharyngeal reflux symptoms.
    J Gastroenterol Hepatol. 2021;36:2076-2082.
    >> Share

    July 2021
  23. CHO JH, Jin SY, Park S
    Scoring model for discriminating gastric cancer risk in patients with negative serum pepsinogen and anti-Helicobacter pylori antibody results.
    J Gastroenterol Hepatol. 2021 Jul 19. doi: 10.1111/jgh.15630.
    >> Share

  24. CHEN Y, Xu C, Xu H, Chen W, et al
    Persistent Helicobacter pylori infection for more than 3 years leads to elevated serum homocysteine concentration: a retrospective cohort study based on a healthy Chinese population.
    J Gastroenterol Hepatol. 2021 Jul 1. doi: 10.1111/jgh.15603.
    >> Share

  25. SUNG JJ
    Clopidogrel is no better or worse than aspirin when combined with proton pump inhibitors in the prevention of major adverse event. Is the jury out?
    J Gastroenterol Hepatol. 2021;36:1733-1734.
    >> Share

    June 2021
  26. HUSSEIN M, Alzoubaidi D, O'Donnell M, de la Serna A, et al
    Hemostatic powder TC-325 treatment of malignancy-related upper gastrointestinal bleeds: International registry outcomes.
    J Gastroenterol Hepatol. 2021 Jun 15. doi: 10.1111/jgh.15579.
    >> Share

  27. GINGOLD-BELFER R, Niv Y, Schmilovitz-Weiss H, Levi Z, et al
    Susceptibility-Guided vs Empirical Treatment for Helicobacter pylori infection: a Systematic Review and Meta-Analysis.
    J Gastroenterol Hepatol. 2021 Jun 11. doi: 10.1111/jgh.15575.
    >> Share

  28. HORII T, Suzuki S, Takano C, Shibuya H, et al
    Lower impact of vonoprazan-amoxicillin dual therapy on gut microbiota for Helicobacter pylori eradication.
    J Gastroenterol Hepatol. 2021 Jun 9. doi: 10.1111/jgh.15572.
    >> Share

    May 2021
  29. JEON HJ, Moon HS, Kwon IS, Kang SH, et al
    Which scoring system should be used for non-variceal upper gastrointestinal bleeding? Old or New?
    J Gastroenterol Hepatol. 2021 May 24. doi: 10.1111/jgh.15555.
    >> Share

    March 2021
  30. QIAO C, Li Y, Liu J, Ji C, et al
    Clarithromycin versus furazolidone for naive Helicobacter pylori infected patients in a high clarithromycin resistance area.
    J Gastroenterol Hepatol. 2021 Mar 10. doi: 10.1111/jgh.15468.
    >> Share

  31. KODAMA M, Okimoto T, Mizukami K, Hirashita Y, et al
    Gastric mucosal changes, and sex differences therein, after Helicobacter pylori eradication: a long-term prospective follow-up study.
    J Gastroenterol Hepatol. 2021 Mar 3. doi: 10.1111/jgh.15477.
    >> Share

    February 2021
  32. AKADA J, Tshibangu-Kabamba E, Tuan VP, Kurogi S, et al
    Serum Helicobacter pylori antibody reactivity in seven Asian countries using an automated latex aggregation turbidity assay.
    J Gastroenterol Hepatol. 2021 Feb 20. doi: 10.1111/jgh.15467.
    >> Share

    January 2021
  33. KATO M, Hayashi Y, Nishida T, Oshita M, et al
    Helicobacter pylori eradication prevents secondary gastric cancer in patients with mild-to-moderate atrophic gastritis.
    J Gastroenterol Hepatol. 2021 Jan 5. doi: 10.1111/jgh.15396.
    >> Share

  34. NIIKURA R, Aoki T, Kojima T, Kawahara T, et al
    Natural history of upper and lower gastrointestinal bleeding in hemodialysis patients: A dual-center long-term cohort study.
    J Gastroenterol Hepatol. 2021;36:112-117.
    >> Share

    November 2020
  35. YANG SC, Wu CK, Tai WC, Liang CM, et al
    Risks of adverse events for users of proton-pump inhibitors plus aspirin or clopidogrel in patients with aspirin-related ulcer bleeding.
    J Gastroenterol Hepatol. 2020 Nov 28. doi: 10.1111/jgh.15360.
    >> Share

  36. SCHUBERT JP, Gehlert J, Rayner CK, Roberts-Thomson IC, et al
    Antibiotic Resistance of Helicobacter pylori in Australia and New Zealand: A Systematic Review and Meta-analysis.
    J Gastroenterol Hepatol. 2020 Nov 20. doi: 10.1111/jgh.15352.
    >> Share

    October 2020
  37. GINGOLD-BELFER R, Niv Y, Levi Z, Boltin D, et al
    Rifabutin triple therapy for first-line and rescue treatment of Helicobacter pylori infection: a systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2020 Oct 10. doi: 10.1111/jgh.15294.
    >> Share

  38. TANG C, Zhu Y, Yang X, Xu B, et al
    Upper gastrointestinal mucosal injury associated with ticagrelor plus aspirin, ticagrelor alone, or aspirin alone at 1-year after coronary artery bypass grafting.
    J Gastroenterol Hepatol. 2020;35:1720-1730.
    >> Share

    September 2020
  39. GRAHAM DY, Lu H, Shiotani A
    Vonoprazan-containing Helicobacter pylori triple therapies contribution to global antimicrobial resistance.
    J Gastroenterol Hepatol. 2020 Sep 12. doi: 10.1111/jgh.15252.
    >> Share

  40. PYO JH, Kim TJ, Lee H, Choi SC, et al
    Proton Pump Inhibitors Use and the Risk of Fatty Liver Disease; A Nationwide Cohort Study.
    J Gastroenterol Hepatol. 2020 Sep 4. doi: 10.1111/jgh.15236.
    >> Share

    August 2020
  41. LI ZX, Ma JL, Guo Y, Liu WD, et al
    Suppression of Helicobacter pylori Infection by Daily Cranberry Intake: A Double-Blind, Randomized, Placebo-Controlled Trial.
    J Gastroenterol Hepatol. 2020 Aug 11. doi: 10.1111/jgh.15212.
    >> Share

    July 2020
  42. CHIANG TH, Maeda M, Yamada H, Chan CC, et al
    Risk Stratification for Gastric Cancer after Helicobacter pylori Eradication: A Population-based Study on Matsu Islands.
    J Gastroenterol Hepatol. 2020 Jul 15. doi: 10.1111/jgh.15187.
    >> Share

  43. KIM TJ, Lee H, Min YW, Min BH, et al
    Cohort Study of Helicobacter Pylori Infection and the Risk of Incident Osteoporosis in Women.
    J Gastroenterol Hepatol. 2020 Jul 13. doi: 10.1111/jgh.15181.
    >> Share

  44. KONO Y, Kusumoto C, Kiguchi T, Okada H, et al
    Gastrointestinal: Rapid emergence of double-expressor lymphoma after Helicobacter pylori eradication therapy.
    J Gastroenterol Hepatol. 2020 Jul 9. doi: 10.1111/jgh.15162.
    >> Share

    June 2020
  45. CHEN G, Ning LJ, Qin Y, Zhao B, et al
    Acute kidney injury following the use of different proton pump inhibitor regimens: A real-world analysis of post-marketing surveillance data.
    J Gastroenterol Hepatol. 2020 Jun 15. doi: 10.1111/jgh.15151.
    >> Share

  46. WONG SH, Yu J
    Proton-pump inhibitor use before fecal microbiota transplant: A wonder drug, a necessary evil, or a needless prescription?
    J Gastroenterol Hepatol. 2020;35:913-914.
    >> Share

    May 2020
  47. ZHENG Y, Xue M, Cai Y, Liao S, et al
    Hospitalizations for Peptic Ulcer Disease in China: Current Features and Outcomes.
    J Gastroenterol Hepatol. 2020 May 25. doi: 10.1111/jgh.15119.
    >> Share

  48. LIN XH, Luo JC, Ting PH, Chang TE, et al
    Comparison of the efficiency of two different proton pump inhibitor formula in treatment of patients with atypical gastroesophageal reflux disease: a prospective randomized study.
    J Gastroenterol Hepatol. 2020 May 13. doi: 10.1111/jgh.15093.
    >> Share

  49. LIN JT
    Reducing the health disparity in gastric cancer: A start by Helicobacter pylori eradication in indigenous peoples living in Taiwan.
    J Gastroenterol Hepatol. 2020;35:705-706.
    >> Share

    April 2020
  50. SUNG JJY
    Population-based screening and mass eradication of Helicobacter pylori infection to prevent gastric cancer: There are more questions than answers.
    J Gastroenterol Hepatol. 2020;35:521-522.
    >> Share

    February 2020
  51. NOH G, Kim N, Choi Y, Lee HS, et al
    Long-term follow-up of serum pepsinogens in patients with gastric cancer or dysplasia after Helicobacter pylori eradication.
    J Gastroenterol Hepatol. 2020 Feb 23. doi: 10.1111/jgh.15017.
    >> Share

  52. NAM JH, Nam SY, Park BJ, Ryu KH, et al
    Effect of Helicobacter pylori Infection and its Eradication on Gastric Regenerating Atypia in 22,133 Subjects.
    J Gastroenterol Hepatol. 2020 Feb 21. doi: 10.1111/jgh.15016.
    >> Share

    January 2020
  53. LIOU JM, Lee YC, Wu MS
    Treatment of Helicobacter pylori infection and its long-term impacts on gut microbiota.
    J Gastroenterol Hepatol. 2020 Jan 26. doi: 10.1111/jgh.14992.
    >> Share

  54. IN SEO S, You SC, Park CH, Kim TJ, et al
    Comparative Risk of Clostridium difficile Infection between Proton Pump Inhibitors and Histamine-2 Receptor Antagonists: A 15-year Hospital Cohort Study Using a Common Data Model.
    J Gastroenterol Hepatol. 2020 Jan 23. doi: 10.1111/jgh.14983.
    >> Share

  55. YIN G, Bie S, Gu H, Shu X, et al
    Application of gene chip technology in the diagnostic and drug resistance detection of Helicobacter pylori in children.
    J Gastroenterol Hepatol. 2020 Jan 12. doi: 10.1111/jgh.14980.
    >> Share

  56. SHUNG DL, Sung JJY
    A new scoring system for upper gastrointestinal bleeding: Too simple or still complicated?
    J Gastroenterol Hepatol. 2020;35:5.
    >> Share

    December 2019
  57. HONG AS, Yu WY, Hong JM, Cross CL, et al
    J Gastroenterol Hepatol. 2019 Dec 12. doi: 10.1111/jgh.14958.
    >> Share

  58. DU Y, Zhu H, Liu J, Li J, et al
    Consensus on eradication of Helicobacter pylori and prevention & control of gastric cancer in China (2019, Shanghai).
    J Gastroenterol Hepatol. 2019 Dec 1. doi: 10.1111/jgh.14947.
    >> Share

    November 2019
  59. MYINT NPST, Zaw TT, Sain K, Waiyan S, et al
    Sequential Helicobacter pylori eradication therapy in Myanmar; a randomized clinical trial of efficacy and tolerability.
    J Gastroenterol Hepatol. 2019 Nov 23. doi: 10.1111/jgh.14942.
    >> Share

  60. NOTSU T, Adachi K, Mishiro T, Ishimura N, et al
    Fundic gland polyp prevalence according to Helicobacter pylori infection status.
    J Gastroenterol Hepatol. 2019 Nov 16. doi: 10.1111/jgh.14934.
    >> Share

  61. WU CK, Yang SC, Liang CM, Li YC, et al
    The role of antibiotics in upper gastrointestinal bleeding among cirrhotic patients without major complications after endoscopic hemostasis.
    J Gastroenterol Hepatol. 2019 Nov 1. doi: 10.1111/jgh.14873.
    >> Share

  62. BAIR MJ, Chuang SL, Lei WY, Chen CL, et al
    Planning Mass Eradication of Helicobacter pylori Infection for Indigenous Taiwanese Peoples to Reduce Gastric Cancer.
    J Gastroenterol Hepatol. 2019 Nov 1. doi: 10.1111/jgh.14898.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016